

**CARBINOXAMINE MALEATE- carbinoxamine maleate solution**  
**IPG Pharmaceuticals, inc.**

-----  
**Carbinoxamine Maleate Oral Solution, 4 mg/5 mL**


**Rx only**

**DESCRIPTION**

Carbinoxamine maleate is a histamine-H<sub>1</sub> receptor blocking agent.

Each 5 mL (teaspoonful) of oral solution contains 4 mg carbinoxamine maleate and the following inactive ingredients: artificial bubble gum flavor, citric acid (anhydrous), glycerin, methylparaben, propylene glycol, propylparaben, purified water, sodium citrate (hydrous) and sorbitol solution.

Carbinoxamine maleate is freely soluble in water. Its structure is:



2-[(4-chlorophenyl)-2-pyridinylmethoxy]- *N,N*- dimethylethanamine(*Z*)-2-butenedioate (1:1)

---

C<sub>16</sub>H<sub>19</sub>ClN<sub>2</sub>O • C<sub>4</sub>H<sub>4</sub>O<sub>4</sub>

MW = 406.86

**CLINICAL PHARMACOLOGY**

**Mechanism of Actions**

Carbinoxamine maleate, an ethanolamine derivative, is an antihistamine with anticholinergic (drying) and sedative properties. Carbinoxamine appears to compete with histamine (type H<sub>1</sub>) for receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract.

**Pharmacokinetics and Metabolism**

Carbinoxamine is well absorbed from the GI tract and appears to be extensively metabolized by the liver, and excreted in the urine as inactive metabolites within 24 hours. Virtually no intact drug is extended in the urine.

In a study comparing a controlled-release suspension and a solution of carbinoxamine, healthy volunteers were administered a single dose of 8 mg carbinoxamine. A time to maximum concentration (T<sub>max</sub>) was between 1.5 hours to 5 hours, a peak plasma concentration (C<sub>max</sub>) of about 24 ng/mL was observed and extent of exposure (AUC) was about 286 ng hr/mL. The serum half-life is reported to be 10 to 20 hours.

### **Drug/Food Interactions**

Carbinoxamine should not be used in patients with hypersensitivity to carbinoxamine. Carbinoxamine may increase the effects of other drugs such as barbiturates, TCAs, MAO inhibitors such as Phenezine (Nardil), Tranylcypromine (Parnate), or Selegiline (Eldepryl), alcohol, other antihistamines, and CNS depressants. Carbinoxamine can be taken with or without food.

### **Cardiovascular Effects**

Cardiac effects, including prolongation of QT interval have not been adequately studied. Unlike other newer antihistamines, severe adverse cardiovascular effects are uncommon, and usually limited to over dosage situations.

### **Special Populations**

#### Pediatric Patients

Carbinoxamine should not be used in newborn or premature infants. Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.

#### Pregnancy and Lactation

Safe use of carbinoxamine during pregnancy has not been established. Therefore, carbinoxamine should not be used in women who are, or may become pregnant. Carbinoxamine is in the FDA pregnancy Category C.

Women who are breast-feeding should avoid use of carbinoxamine, since small amounts appear to be distributed into breast milk.

#### Geriatric Patients

Carbinoxamine is more likely to cause dizziness, sedation, and hypotension in elderly patients. The incidence of adverse reactions is higher in the elderly; therefore, a dosing adjustment may be necessary in this sub-population.

## **INDICATIONS AND USAGE**

Carbinoxamine maleate is effective for the symptomatic treatment of:

Seasonal and perennial allergic rhinitis.

Vasomotor rhinitis.

Allergic conjunctivitis due to inhalant allergens and foods.

Mild, uncomplicated allergic skin manifestations of urticaria and angioedema.

Dermatographism.

As therapy for anaphylactic reactions *adjunctive* to epinephrine and other standard measures after the acute manifestations have been controlled.

Amelioration of the severity of allergic reactions to blood or plasma.

## **CONTRAINDICATIONS**

Carbinoxamine maleate is contraindicated in children younger than 2 years of age.

Carbinoxamine maleate is contraindicated in nursing mothers.

Carbinoxamine maleate is contraindicated in patients who are hypersensitive to the drug or on monoamine oxidase inhibitor therapy. (See Drug Interactions section).

## **WARNINGS**

Deaths have been reported in children less than 2 years of age who were taking antihistamines, including carbinoxamine-containing drug products, therefore, carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

Antihistamines should be used with considerable caution in patients with: narrow angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction.

## **PRECAUTIONS**

### **General**

As many other antihistamines, carbinoxamine maleate has an atropine-like action and, therefore, should be used with caution in patients with: increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension.

Antihistamines such as carbinoxamine maleate should not be used to treat lower respiratory tract symptoms, including asthma.

### **Information for Patients**

Carbinoxamine maleate may cause drowsiness; alcohol, sedatives, and tranquilizers may increase the drowsiness effect. Avoid alcoholic beverages while taking this product. Do not take this product if you are taking sedatives or tranquilizers, without first consulting your doctor. Use caution when driving a motor vehicle or operating machinery.

### **Drug Interactions**

Monoamine oxidase inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

Carbinoxamine maleate has additive effects with alcohol and other CNS depressants (hypnotics sedatives, tranquilizers, etc.).

## **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term studies in animals have been performed to determine the possible effects of carbinoxamine maleate on carcinogenesis, mutagenesis, and fertility.

## **Pregnancy**

Pregnancy Category C

Animal reproductive studies have not been conducted with carbinoxamine maleate. It is also not known whether carbinoxamine maleate can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Carbinoxamine maleate should be given to a pregnant woman only if clearly needed.

## **Nursing Mothers**

Because of the higher risk of antihistamines for infants generally and for newborns and prematures in particular, use of carbinoxamine maleate is contraindicated in nursing mothers (see CONTRAINDICATIONS section).

## **Pediatric Use**

Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

Neonates have an increased susceptibility to anticholinergic side effects, such as CNS excitation, which may lead to convulsions.

Carbinoxamine maleate may diminish mental alertness in children. In the young child, particularly, they may produce excitation.

## **Geriatric Use**

Carbinoxamine maleate is more likely to cause dizziness, sedation, and hypotension in elderly patients (approximately 60 years or older). Sedating drugs may also cause confusion and over sedation in the elderly. Therefore, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic renal, or cardiac function, and of concomitant disease or other drug therapy.

## **ADVERSE REACTIONS**

The most frequent adverse reactions are underlined:

*Body as a Whole:* Urticaria, drug rash, anaphylactic shock, photosensitivity, excessive perspiration, chills, dryness of mouth, nose and throat.

*Cardiovascular:* Hypotension, headache, palpitations, tachycardia, extrasystoles.

*Hematologic:* Hemolytic anemia, thrombocytopenia, agranulocytosis.

*Central Nervous System:* Sedation, sleepiness, dizziness, disturbed coordination, fatigue, confusion, restlessness, excitation, nervousness, tremor, irritability, insomnia, euphoria, paresthesia, blurred vision, diplopia, vertigo, tinnitus, acute labyrinthitis, hysteria, neuritis, convulsions.

*Gastrointestinal:* Epigastric distress, anorexia, nausea, vomiting, diarrhea, constipation.

*Urogenital:* Urinary frequency, difficult urination, urinary retention, early menses.

*Respiratory:* Thickening of bronchial secretions, tightness of chest and wheezing, nasal stuffiness.

**To report SUSPECTED ADVERSE REACTIONS, contact IPG Pharmaceuticals, Inc. at 1-888-711-7116 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

## **OVERDOSAGE**

### **Manifestations**

Antihistamine overdose reactions may vary from central nervous system depression to stimulation. Stimulation is particularly likely in children. Atropine-like signs and symptoms - dry mouth; fixed, dilated pupils; flushing; and gastrointestinal symptoms may also occur.

Especially in infants and children, antihistamine overdose may cause hallucinations, convulsions, or death.

The oral LD<sub>50</sub> of carbinoxamine maleate in guinea pigs is 411 mg/kg.

### **Treatment**

The treatment of overdose with carbinoxamine maleate is essentially symptomatic and supportive. Vital signs (including respiration, pulse, blood pressure, and temperature) and EKG should be monitored. Induction of vomiting is not recommended. Activated charcoal should be given and gastric lavage should be considered after ingestion of a potentially life-threatening amount of drug. In the presence of severe anticholinergic effects, physostigmine may be useful. Vasopressors may be used to treat hypotension.

## **DOSAGE AND ADMINISTRATION**

Carbinoxamine maleate is contraindicated in children younger than 2 years of age (see CONTRAINDICATIONS).

Carbinoxamine maleate should be taken on an empty stomach with water.

**DOSAGE SHOULD BE INDIVIDUALIZED ACCORDING TO THE NEEDS AND THE RESPONSE OF THE PATIENT.**

Carbinoxamine maleate dosage should be based on the severity of the condition and the response of the patient. The drug is well tolerated in adults in doses as high as 24 mg daily, in divided doses, over prolonged periods. On the other hand, some patients respond to as little as 4 mg daily.

Clinical experience suggests the following dosage schedules:

### **Oral Solution**

Usual Adult Dosage:

1 or 2 teaspoonfuls (4 to 8 mg) 3 to 4 times daily

Usual Child's Dosage (approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 doses):

Six to eleven years- ½ to 1 teaspoonful (2 to 4 mg) 3 to 4 times daily.

Dosing for children 2 to 5 years of age should be based on weight whenever possible. The usual dosage for children 2 to 5 years of age is

approximately 0.2 to 0.4 mg/kg/day, divided into 3 to 4 daily doses. In general, this corresponds to a dose of ¼ to ½ teaspoonful (1 to 2 mg) 3

to 4 times daily.

## **HOW SUPPLIED**

Carbinoxamine Maleate Oral Solution, 4 mg/5 mL is supplied as clear, colorless liquid with a bubble gum aroma, and is supplied in 4 fl. oz. bottles, NDC 71085-080-07 and in 16 fl. oz. bottles, NDC 71085-080-07.

Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].

Dispense in a tight, light-resistant container with a child-resistant closure as defined in the official compendium.

### **Manufactured for:**

IPG Pharmaceuticals, Inc.  
Tempe, AZ 85281

## **Product label**

NDC 71085-080-07

**RX Only**

**IPG**

# CARBZAH

4 mg/5 mL

CARBINOXAMINE  
MALEATE ORAL  
SOLUTION

Each 5 mL (one teaspoonful)  
for oral administration  
contains 4 mg of  
carbinoxamine maleate, USP

**16 fl. oz. (473 mL)**

**USUAL DOSAGE:** See package insert for full prescribing information.

**WARNING:** Keep this and all medications out of reach of children.

**PHARMACIST:** Dispense in a tight, light-resistant container with a child-resistant closure.

**STORAGE:** Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

Manufactured for:  
**IPG Pharmaceuticals, Inc.**  
Tempe, AZ 85281

Rev. 05/2025



2D Code  
GTIN  
Lot  
Exp

**QUESTIONS OR COMMENTS?**  
Call 1-888-711-7116

## CARBINOXAMINE MALEATE

carbinoxamine maleate solution

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:71085-080
<b>Route of Administration</b>	ORAL		

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
-----------------	-------------------	----------

<b>CARBINOXAMINE MALEATE</b> (UNII: 02O55696WH) (CARBINOXAMINE - UNII:982A7M02H5)	CARBINOXAMINE MALEATE	4 mg in 5 mL
---	-----------------------	-----------------

<b>Inactive Ingredients</b>	
<b>Ingredient Name</b>	<b>Strength</b>
<b>ANHYDROUS CITRIC ACID</b> (UNII: XF417D3PSL)	
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	
<b>METHYLPARABEN</b> (UNII: A2I8C7HI9T)	
<b>PROPYLENE GLYCOL</b> (UNII: 6DC9Q167V3)	
<b>PROPYLPARABEN</b> (UNII: Z8IX2SC1OH)	
<b>SODIUM CITRATE, UNSPECIFIED FORM</b> (UNII: 1Q73Q2JULR)	
<b>SORBITOL</b> (UNII: 506T60A25R)	
<b>WATER</b> (UNII: 059QF0KO0R)	

<b>Product Characteristics</b>			
<b>Color</b>		<b>Score</b>	
<b>Shape</b>		<b>Size</b>	
<b>Flavor</b>	BUBBLE GUM	<b>Imprint Code</b>	
<b>Contains</b>			

<b>Packaging</b>				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:71085-080-07	473 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	06/01/2025	

<b>Marketing Information</b>			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA040458	06/01/2025	

**Labeler** - IPG Pharmaceuticals, inc. (080441238)

Revised: 5/2025

IPG Pharmaceuticals, inc.